THE OPTIMIZED HINGE CD19/20 CAR-T SHOWED DURABLE EFFICACY in PATIENTS with RELAPSED/REFRACTORY B-CELL LYMPHOMA: INTERIM RESULTS from A MULTICENTER PHASE I/II TRIAL

Category Primary study
ConferenceThe 51st Annual Meeting of the European Society for Blood and Marrow Transplantation
Year 2025
This article has no abstract
Epistemonikos ID: 2dd1f9a9b74056e0dd11828acdeb8c208981bf1b
First added on: Jan 10, 2026